| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444974 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
This study demonstrates tolerability and durable clinical benefit of bortezomib when given at 1.5Â mg/m2 biweekly. Despite a higher response rate in the biweekly arm, no major difference in patient's outcome was observed between the two arms in the final analysis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, André Bosly, Reda Bouabdallah, Richard Delarue, François Boue, Dominique Bron, Pierre Feugier, Corinne Haioun, Firtz Offner, Bertrand Coiffier,